Manufacturing
Trust us for unparalleled expertise in pharmaceutical raw materials and pharmaceutical intermediates
About TianmingOur comprehensive range includes Cardiovascular, DiabetesAnti-Tumor, and Anti-Aging Solutions
Explore productsOur commitment to quality and excellence ensures that our pharmaceutical intermediates meet the highest standards
Explore productsSpecializes in providing tailored pharmaceutical intermediates and custom synthesis services to meet your specific requirements
Experience serviceWho We Are
Pharmaceutical raw materials and active pharmaceutical ingredients manufacturers
Tianming Pharmaceutical is a leading company in the research, development, production, and sales of new drugs. Specializing in chemical intermediates, pharmaceutical chemicals, and raw materials, we are trusted active pharmaceutical ingredient suppliers for antibiotics, cardiovascular, diabetes, anti-tumor, anti-aging, and antiviral drugs.
What We Do
Transforming Health with Premium Pharmaceutical Solutions
Advanced Drug R&D
Our team pioneers in discovering and developing new drugs, focusing on antibiotics, cardiovascular, diabetes, anti-tumor, anti-aging, and antiviral treatments.
High-Quality Manufacturing
We maintain rigorous quality control across all production processes, guaranteeing the highest standards for our chemical intermediates and pharmaceutical raw materials.
Comprehensive Global Distribution
We provide active pharmaceutical ingredients, technical consulting, collaborative R&D and other services to global customers to meet diverse market needs.
Our Products
Popular categories
Antiviral
Antiviral products and their intermediates (baloxavir fumarate, nafamostat mesylate, mupiravir, etc.)
Diabetes
Diabetes API and their intermediates (alogliptin, linagliptin, empagliflozin, etc.)
Anti-tumor
Anti-tumor API and their intermediates (ibrutinib, baricitinib, tofacitinib, etc.)
Cardiovascular
Cardiovascular API and their intermediates (LCZ696, AHU377 calcium salt, etc.)
What's News
Latest news at Tianming
Long-Term Side Effects of Ibrutinib: What the Latest Research Shows
This article summarizes 2025 latest research on ibrutinib’s long-term side effects, covering atrial fibrillation, bleeding, hypertension, infections and joint issues. It compares safety with newer BTK inhibitors and notes real-world treatment discontinuation risks.
Orforglipron vs Retatrutide: A Tale of Two Next-Generation GLP-1s
Orforglipron vs retatrutide: oral small‑molecule GLP‑1 agonist vs triple‑hormone injectable. Phase 3 weight loss data, dosing schedules, side effects, regulatory status, and API manufacturing differences.
Regulatory Differences Between API and Intermediate Manufacturing: A Practical Guide
Regulatory differences between API and intermediate manufacturing under ICH Q7, FDA, EMA, and NMPA. GMP boundaries, DMF filing, starting material justification.
